New pharmacological treatments for obesity: incretin analogues, their mechanism of action, efficacy and safety Medicine Today PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling MM+M Medical Marketing and Media Cagrilintide Limitless Labs